Mivelsiran

N/A

Report date: 2024/11/21 11:44:07
NME

Base Information

Drug NameMivelsiran
Drug Alias NameALN-APP
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer DiseaseCerebral Amyloid Angiopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSirna Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlnylam Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAlzheimer DiseaseCerebral Amyloid Angiopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A